|Bid||745.20 x 0|
|Ask||0.00 x 0|
|Day's Range||727.00 - 727.00|
|52 Week Range||727.00 - 727.30|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Kite stock jumped for the third straight day Thursday after rival Novartis presented data on a cancer drug that would have to be 20% better to hurt Kite.
Two cutting-edge treatments for blood cancers are poised to get approved by the end of the...
Celgene stock dipped to a four-month low Monday after ozanimod failed to show a disability benefit over interferon in multiple sclerosis patients.
Novartis is exercising its option with Conatus Pharmaceuticals for an exclusive license for the global development and commercialization of emricasan for treating liver disease NASH, the Swiss drugmaker said. In December, Novartis said it signed a licensing deal to co-develop the fatty liver disease drug with Conatus, under which the small U.S. company receives $50 million up front.
Eli Lilly is set to outperform bigger drugmakers Novartis and Sanofi in terms of first-quarter diabetes sales.
Swiss drugmaker Novartis AG expects growth in China’s pharmaceuticals market to accelerate as the nation’s health authorities expedite approvals for new medicines and increase reimbursement.
The data to emerge from Novartis' JULIET study is of keen interest to investors because it will be compared against Kite Pharma's competing "CAR-T" KTE-C19 in the same DLBCL patients.
Novartis's push into oncology and liver disease, two of its treatment priorities, advanced on Monday as the Swiss drugmaker won a second U.S. breakthrough tag for its cancer gene therapy while striking a separate pact with Allergan. The Basel-based drugmaker's chimeric antigen receptor therapy (CAR-T) treatment, called CTL019, was awarded the U.S. Food and Drug Administration's breakthrough therapy designation for adults with relapsed/refractory (r/r) diffuse large B-cell lymphoma, a common blood cancer.
Novartis (NVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The 10 most profitable companies in Europe are responsible for some of the top-class products and services that are being provided on just about every continent in the world. Out of the 10 companies on this list, four are from Switzerland, while three are from Germany, reflective of the favorable position of the two countries […]
With Novartis (NVS) being a Zacks Rank #4 (Sell) stock, here is a look at two European pharma stocks that sport a strong Zacks Rank.
Johnson & Johnson, Abbott Labs, AbbVie, Novo Nordisk, and Novartis rank as the top drug stocks with the best dividend track records.
Novartis AG (NVS) recently announced that it has exercised an option to in-license ECF843 for ophthalmic indications worldwide from Lubris LLC.